O R I G I N A L A R T I C L E Annals Gastroenterology 2015 28 118123 Value 3 Tesla diffusionweighted magnetic resonance imaging assessing liver fibrosis Lavrentios Papalavrentiosa Emmanouil Sinakosa Danai Chourmouzib Prodromos Hytiroglouc Konstantinos Drevelegasb Manos Constantinidesb Antonios Drevelegasb Jayant Talwalkard Evangelos Akriviadisa University Thessaloniki Greece Interbalkan Medical Center Thessaloniki Greece Mayo Clinic Rochester Rochester MN USA Abstract Background Limited data available role magnetic resonance imaging MRI particularly new generation 3 Tesla technology especially diffusionweighted imaging DWI predicting liver fibrosis The aim pilot study assess clinical performance apparent diffusion coefficient ADC liver parenchyma assessment liver fibrosis patients nonalcoholic fatty liver disease NAFLD Methods 18 patients biopsyproven NAFLD underwent DWI 3 Tesla MRI DWI performed singleshot echoplanar technique b values 0500 01000 smm2 ADC measured locations liver mean ADC value analysis Staging fibrosis performed according METAVIR Results The median age patients 52 years range 2373 The distribution patients different fibrosis stages 0 n1 1 n7 2 n1 3 n5 4 n4 Fibrosis stage poorly associated ADC b value 0500 smm2 r 030 P027 However significantly associated ADC b value 01000 smm2 r 057 P001 For b value 01000 smm2 area receiveroperating characteristic curve 093 fibrosis stage 3 optimal ADC cutoff value 116 103 mm2s Conclusion 3 Tesla DWI possibly predict presence advanced fibrosis patients NAFLD Keywords Liver fibrosis nonalcoholic fatty liver diffusionweighted imaging 3 Tesla Ann Gastroenterol 2015 28 1 118123 Introduction Nonalcoholic fatty liver disease NAFLD currently prevalent cause liver disease Western countries The development nonalcoholic steatohepatitis NASH fibrosis identifies group increased risk liverrelated a4th Internal Medicine Unit University Thessaloniki Lavrentios Papalavrentios Emmanouil Sinakos Evangelos Akriviadis bDepartment Radiology Interbalkan Medical Center Thessaloniki Danai Chourmouzi Konstantinos Drevelegas Manos Constantinides Antonios Drevelegas cDepartment Pathology University Thessaloniki Prodromos Hytiroglou Greece dDivision Gastroenterology Hepatology Mayo Clinic Rochester Rochester MN USA Jayant Talwalkar Conflict Interest None Correspondence Lavrentios Papalavrentios MD Samanidi 36 Panorama Thessaloniki Greece Tel 30 2310 342046 Fax 30 2310 471056 email lpapalavrentiosyahoocom Received 2 March 2014 accepted 20 July 2014 deaths cirrhosis hepatocellular carcinoma The prevalence NAFLD estimated 20 30 Western countries 12 rising 90 morbidly obese patients 3 NASH advanced clinically important form NAFLD common estimated prevalence 23 general population 4 37 morbidly obese 3 Liver biopsy currently gold standard guide therapeutic decisions assess prognosis patients NAFLD The development noninvasive methods liver fibrosis evaluation aims reduce biopsyrelated risk cost facilitate improved monitoring disease progression Serological assays Fibrotest radiological methods like transient elastography Fibroscan Echosens France increasingly evaluate liver fibrosis NAFLD chronic liver diseases Magnetic resonance imaging MRI evaluated noninvasive method liver fibrosis assessment Recently MR elastography demonstrated excellent diagnostic accuracy sensitivity specificity 98 99 respectively detecting grades fibrosis 5 2015 Hellenic Society Gastroenterology wwwannalsgastrogr Another MRI technique diffusionweighted imaging DWI lately liver fibrosis assessment Diffusion physical property describes microscopic random movement water molecules driven internal thermal energy Diffusion quantitatively reflected diffusion coefficient apparent diffusion coefficient ADC expressed mm2s Conflicting results reliability DWI apparent diffusion coefficient ADC values liver fibrosis staging patients chronic liver disease reported 67 studies shown decrease hepatic ADC liver cirrhosis 810 The aim study assess clinical performance DWI performed 3 Tesla MRI scanners assessment liver fibrosis patients NAFLD Patients methods Patients We included patients biopsyproven NAFLD study Patients positive hepatitis B surface antigen antihepatitis C virus antibody histological evidence concomitant liver disease excluded study Patients alcohol consumption 40 gday excluded All patients underwent percutaneous liver biopsy LB DWI 3month interval Anthropometric tests included body weight body height waist circumference measurements Body mass index BMI calculated weight divided height m squared On day liver biopsy fasting venous blood sample taken aspartate aminotransferase AST alanine aminotransferase ALT alkaline phosphatase ALP total bilirubin albumin glucose total cholesterol triglycerides DWI DWI performed 3 Tesla MRI scanner SIgna HDxT General Electric Milwaukee aid 8 channel Torso phasedarray coil Diffusion cases acquired respiratory gating Single Shot Echo Planar Imaging DWEPI pulse sequence Parallel imaging Array Spatial Sensitivity Encoding Technique ASSET factor 2 improve image quality DWI performed axial plane tridirectional diffusion gradients b values 0 500 1000 smm2 The repetition time TR average 10288 ms 8571 13330 echo time TE 637 679 ms slice thickness 6 mm gap slices 1 mm matrix 128 128 field view 400 mm number excitations 4 The total acquisition time average 45 min The ADC maps calculated commercial workstation software GE Healthcare random locations liver 12 cm2 regions away intrahepatic vasculature Mean ADC values analysis Fig 1 Diffusionweighted MRI liver fibrosis 119 Figure 1 Diffusionweighted image apparent diffusion coefficient map obtained b value 01000 smm2 63yearold woman nonalcoholic fatty liver disease fibrosis stage 3 Liver biopsy LB procedures performed experienced physicians intercostal approach 16 18 mm diameter Menghini needles All biopsies 15 cm length evaluated experienced liver pathologists METAVIR scoring staging fibrosis 0 4 stage 0absence fibrosis stage 1perisinusoidal portal stage 2perisinusoidal portalperiportal stage3 septal bridging fibrosis stage 4cirrhosis Grade liver steatosis defined according Kleiner et al 0steatosis 5 15 33 2steatosis 3366 3steatosis 66 11 Statistical analysis Continuous variables presented means standard deviation median range frequency data presented number percentage The correlations ADC different variables explored Spearmans ρ correlation The performance ADC assessed receiver operator characteristic ROC curve Based ROC curve cutoff value designated ADC maximize sensitivity specificity assay Results Table 1 summarizes baseline patients characteristics 18 patients included study The median age patients 52 years range 2373 The mean BMI 281 kgm2 range 203382 78 percent subjects male The median values AST ALT glucose cholesterol triglyceride albumin total bilirubin alkaline phosphatase levels 375 IUL 18132 58 IUL 19132 98 mgdL 86176 217 mgdL 169275 150 mgdL 77305 45 gdL 4149 07 mgdL 0114 108 IUL 57330 respectively The distribution patients different fibrosis stages 0 n1 1 n7 2 n1 3 n5 4 n4 Degree steatosis 0 n0 1n7 2n3 3n8 Annals Gastroenterology 28 120 L Papalavrentios et al Table 1 Patients characteristics N Age years Male gender n Body mass index Alkaline phosphatase IUL Albumin gdL Total bilirubin mgdL Cholesterol mgdL Triglycerides mgdL AST IUL ALT IUL Glucose mgdL 18 52 2373 14 78 281 201382 108 57330 45 4149 07 0114 217 169275 98 86176 375 18132 58 19132 98 86176 NB Data presented median range indicated ADC correlation clinical variables DWI examination technically successful patients Data processing possible subjects ADC b value 01000 smm2 significant inverse correlation age r066 P0002 It correlated anthropometric characters like BMI waist circumference r047 P004 r046 P005 respectively Total cholesterol AST levels laboratory values showed relationship ADC r053 P005 r058 P001 respectively All relationships significant ADC b value 0500 smm2 ADC correlation histological parameters Steatosis associated ADC b value 0500 smm2 P064 b value 01000 smm2 P009 Fibrosis stage poorly associated ADC b value 0500 smm2 r 030 P027 significantly associated ADC b value 01000 smm2 r 057 P001 For b value 01000 smm2 area ROC curve 093 fibrosis stage 3 optimal ADC cutoff value 116 103 mm2s maximizing sum sensitivity specificity positive predictive value 100 negative predictive value 90 Fig 2 3 Namely patient fibrosis stage 3 ADC value lower 116 103 mm2s 1 patient fibrosis stage 3 ADC value greater 116 103 mm2s Significant decrease ADC values seen patients fibrosis stage 3 versus fibrosis stage 2 especially b value 01000 smm2 Table 2 The ability discriminate fibrosis stage 2 b value 01000 smm2 good area ROC curve 088 As sample patients similar patient fibrosis stage 2 groups fibrosis stage 3 2 optimal ADC cutoff value group patients 116 103 mm2s different predictive values positive predictive value 100 negative predictive value 80 However ability diagnose cid72 cid89 cid76 cid87 cid76 cid86 cid82 cid51 cid3 cid72 cid88 cid85 cid55 cid92 cid87 cid76 cid89 cid76 cid87 cid76 cid86 cid81 cid72 cid86 cid20cid15cid19cid19 cid19cid15cid28cid19 cid19cid15cid27cid19 cid19cid15cid26cid19 cid19cid15cid25cid19 cid19cid15cid24cid19 cid19cid15cid23cid19 cid19cid15cid22cid19 cid19cid15cid21cid19 cid19cid15cid20cid19 cid19cid15cid19cid19 cid19cid15cid19cid19 cid19cid15cid21cid19 cid19cid15cid23cid19 cid19cid15cid25cid19 cid19cid15cid27cid19 cid20cid15cid19cid19 cid20cid16cid54cid83cid72cid70cid76cid73cid76cid70cid76cid87cid92 cid41cid68cid79cid86cid72cid3cid51cid82cid86cid76cid87cid76cid89cid72 Figure 2 Receiver operating characteristics curve fibrosis stage 3 b value 0500 smm2 cid72 cid89 cid76 cid87 cid76 cid86 cid82 cid51 cid3 cid72 cid88 cid85 cid55 cid92 cid87 cid76 cid89 cid76 cid87 cid76 cid86 cid81 cid72 cid86 cid20cid15cid19cid19 cid19cid15cid28cid19 cid19cid15cid27cid19 cid19cid15cid26cid19 cid19cid15cid25cid19 cid19cid15cid24cid19 cid19cid15cid23cid19 cid19cid15cid22cid19 cid19cid15cid21cid19 cid19cid15cid20cid19 cid19cid15cid19cid19 cid19cid15cid19cid19 cid19cid15cid21cid19 cid19cid15cid23cid19 cid19cid15cid25cid19 cid19cid15cid27cid19 cid20cid15cid19cid19 cid20cid16cid54cid83cid72cid70cid76cid73cid76cid70cid76cid87cid92 cid41cid68cid79cid86cid72cid3cid51cid82cid86cid76cid87cid76cid89cid72 Figure 3 Receiver operating characteristics curve fibrosis stage 3 b value 01000 smm2 cirrhosis fibrosis stage 4 poor area ROC curve 064 positive predictive value 43 exclusion condition safely predicted negative predictive value 91 Discussion The diagnosis treatment patients NAFLD depends significantly liver fibrosis staging Liver biopsy considered gold standard assessment liver fibrosis currently recommended professional society practice guidelines Although generally safe procedure invasive minor possibility adverse events hemorrhage death 12 In addition accuracy liver biopsy varies significantly depending interobserver variability sampling error This results 30 false negative results underestimation cirrhosis especially small 15cm fragmented specimens 1316 During decade number non invasive methods liver fibrosis assessment introduced MRI methods like MR elastography spectroscopy DWI evaluated non invasive methods liver fibrosis assessment Advantages MRI methods include ability Annals Gastroenterology 28 scan liver minimize sampling error lack requirement acoustic window transient elastography insensitivity body habitus ascites finally ability obtain conventional MRI setting DWI affected biophysical properties tissue cell organization cell membranes fibers macromolecules density microstructure microcirculation Pathological processes change volume ratio physical nature intra extracellular spaces affect diffusion water molecules Restricted impeded diffusion seen tissues high cellularity tumors abscesses fibrosis cytotoxic edema Relative free unimpeded diffusion encountered tissues low cellularity tissues disrupted cell membranes example cysts necrotic tissues 1720 Low ADC values mean restricted diffusion tissues highly cellular High ADC values seen areas relative free diffusion tissues low cellularity DWI performed current generation scanners 1 5 Tesla appear reliable replace liver biopsy 21 Theoretically new generation 3 Tesla technology improve hepatic ADC detection 22 The increased signal noise ratio inherent 3 Tesla scanners provides higher sensitivity areas restricted diffusion use parallel imaging reduction TE reduces susceptibility artifacts 2324 Our study showed significant inverse correlation liver fibrosis ADC values taken 3 Tesla DWI NAFLD patients This correlation significantly associated ADC b value 01000 smm2 ADC cutoff value 116 103 mm2s shown predict severe fibrosis stage 3 providing potentially useful tool assessment patients To knowledge reports liver fibrosis correlation ADC values performed 3 Tesla MRI scanners patients chronic liver disease The included 37 patients chronic viral hepatitis 34 healthy volunteers The authors reported significant inverse correlation ADC values liver fibrosis b factor 1000 smm2 25 The second included 55 patients chronic liver disease undergone DWI 8 bvalues 3 Tesla Significant correlation ADC values hepatic fibrosis reported Higher ADC values seen fibrosis stage F1 compared fibrosis stage F4 26 Conflicting results liver fibrosis DWI 15 Tesla scanners reported Taouli et al 7 reported significant inverse correlation ADC liver fibrosis patients chronic liver disease AUC 0896 cut value 103 103 mm2s 01000 b value fibrosis stage 3 Koinuma et al 27 evaluated large population patients n163 31 underwent liver biopsy significant inverse correlation hepatic ADC fibrosis stage lower b value 128 smm2 Sandrasegaran et al 21 reported significantly lower ADCs cirrhotic livers compared nonfibrotic livers ADC values useful differentiating patients fibrosis stage 2 lower degree fibrosis Lewin et al 28 compared DWI 54 hepatitis C patients 20 healthy volunteers Diffusionweighted MRI liver fibrosis 121 FibroScan FibroTest They DWI comparable tests detecting severe fibrosis reported significant overlap ADC values patients mild moderate fibrosis Bakan et al 29 reported lower ADC values associated higher fibrosis stages 34 patients chronic liver disease Bonekamp et al 30 liver ADC values inversely correlated fibrosis stage AUROCs 079 077 077 079 obtained fibrosis stages 123 4 respectively This study shows ADC b value 01000 smm2 statistically significant inverse correlation liver fibrosis compared b value 0500 smm2 The sensitivity DWI sequence characterized b value The higher b value sensitive sequence diffusion effects 2131 Boulanger et al 32 DWI b values 50250 smm2 18 chronic hepatitis C patients 10 control subjects They significant difference groups Interestingly ADCs patients hepatitis C higher controls It possible differences fibrotic nonfibrotic liver detected small b values 300 smm2 increase perfusion contamination ADC measurement 3133 In recent study including 24 patients chronic liver disease 22 healthy volunteers ADC values b value 750 smm2 greater showed superior correlation liver fibrosis compared lower b values 34 On hand researchers believe advantage calculating ADC values intermediate b value compared higher b value 35 According results believe 3 Tesla DWI b value 1000 smm2 provides relative advantage liver fibrosis assessment compared 15 Tesla technology scanners We acknowledge limitations study First pilot study report preliminary experience small number patients Also DWI expensive non invasive methods liver fibrosis assessment comparable effectiveness In addition MRE shown superior predicting liver fibrosis compared DWI recently published metaanalysis 36 However studies included analysis performed 15 Tesla scanners As recently pointed strength magnetic field scanner uses plays vital role interpreting results 37 In conclusion findings suggest 3 Tesla DWI possibly predict presence advanced 3 fibrosis patients NAFLD especially b value 01000 smm2 Future work needed assess larger number Table 2 Comparison liver apparent diffusion coefficient ADC value103 mm2s fibrosis stage 2 3 n18 Fibrosis stage b value 0500 b value 01000 2 3 P 161016 139018 005 130008 106014 0001 NB Liver ADC decrease statistically significant patients advanced fibrosis b values 1000 smm2 Annals Gastroenterology 28 122 L Papalavrentios et al Summary Box What known imaging DWI Diffusionweighted evaluated increasingly decade alternative liver biopsy staging liver fibrosis Conflicting results DWIs efficacy predicting liver fibrosis reported The majority reports performed 15 Tesla scanners Only reports 3 Tesla scanners available patients chronic viral hepatitis What new findings The present study performed 3 Tesla magnetic resonance imaging scanner including patients NAFLD The b value 01000 smm2 shown superior liver fibrosis staging This study Greek population patients NAFLD correlate 3 Tesla DWI findings liver fibrosis These new technology scanners provide useful tool treatment follow subset patients References 1 Browning JD Szczepaniak LS Dobbins R et al Prevalence hepatic steatosis urban population United States impact ethnicity Hepatology 20044013871395 2 Bedogni G Miglioli L Masutti F et al Prevalence risk factors nonalcoholic fatty liver disease Dionysos nutrition liver study Hepatology 2005424452 3 Machado M MarquesVidal P CortezPinto H Hepatic histology obese patients undergoing bariatric surgery J Hepatol 200645600606 4 NeuschwanderTetri SH Nonalcoholic steatohepatitis summary AASLD Single Topic Conference Hepatology 20033712021219 Caldwell BA 5 Yin M Talwalkar JA Glaser KJ et al Assessment hepatic fibrosis magnetic resonance elastography Clin Gastroenterol Hepatol 2007512071213 6 Taouli B Ehman RL Reeder SB Advanced MRI Methods Assessment Chronic Liver Disease AJR 20091931427 7 Taouli B Tolia A Losada M et al DiffusionWeighted MRI Quantification Liver Fibrosis Preliminary Experience AJR 2007189799806 8 Namimoto T Yamashita Y Sumi S et al Focal liver masses characterization diffusionweighted echoplanar MR imaging Radiology 1997204739744 imaging singleshot echoplanar sequence detection characterization focal hepatic lesions AJR 1998170397402 10 Amano Y Kumazaki T Ishihara M Singleshot diffusionweighted echoplanar imaging normal cirrhotic livers phased array multicoil Acta Radiol 199839440442 11 Kleiner DE Brunt EM Van Natta M et al Design validation histological scoring nonalcoholic fatty liver disease Hepatology 20054113131321 12 Bravoo AA Sheth S Chopra S Liver biopsy N Engl J Med 2001344495500 13 Castéra L Nègre I Samii K et al Pain experienced percutaneous liver biopsy Hepatology 19993015291530 14 Colloredo G Guido M Sonzogni A et al Impact liver biopsy size histological evaluation chronic viral hepatitis smaller sample milder disease J Hepatol 200339239244 15 Regev A Berho M Jeffers LJ et al Sampling error intraobserver variation liver biopsy patients chronic HCV infection Am J Gastroenterol 20029726142618 16 Siddique I ElNaga HA Madda JP et al Sampling variability percutaneous liver biopsy patients chronic hepatitis C virus infection Scand J Gastroenterol 200338427432 17 Kele PG van der Jagt EJ Diffusion weighted imaging liver World J Gastroenterol 20101615671576 18 CharlesEdwards EM deSouza NM Diffusionweighted magnetic resonance imaging application cancer Cancer Imaging 20066135143 19 Thoeny HC De Keyzer F Extracranial applications diffusionweighted magnetic resonance imaging Eur Radiol 20071713851393 20 Kwee TC Takahara T Ochiai R et al Diffusionweighted body imaging background body signal suppression DWIBS features potential applications oncology Eur Radiol 20081819371952 21 Sandrasegaran K Akisik FM Lin C et al Value Diffusion Weighted MRI Assessing Liver Fibrosis Cirrhosis AJR 200919315561560 22 Taouli B Martin AJ Qayyum A et al Parallel imaging diffusion tensor imaging diffusionweighted MRI liver preliminary experience healthy volunteers AJR 2004183677680 23 Chang K Kamel I Macura K Bluemke D 30T MR Imaging Abdomen Comparison 15 T Radiographics 20082819831998 24 Erturk SM AlberichBayarri A Hermann KA MartinBonnati L Ros PR Use 30T MR imaging evaluation abdomen Radiographics 20092915471563 25 Tosun M Inan N Sarisoy HT et al Diagnostic performance conventional diffusion weighted imaging diffusion tensor imaging liver fibrosis inflammation Eur J Radiol 201382203207 26 Yoon JH Lee JM Baek JH et al Evaluation hepatic fibrosis intravoxel incoherent motion diffusionweighted liver MRI J Comput Assist Tomogr 201438110116 27 Koinuma M Ohashi I Hanafusa K et al Apparent diffusion coefficient measurements diffusionweighted magnetic resonance imaging evaluation hepatic fibrosis J Magn Reson Imaging 2005228085 28 Lewin M PoujolRobert A Boelle PY et al Diffusionweighted magnetic resonance imaging assessment fibrosis chronic hepatitis C Hepatology 200746658665 29 Bakan AA Inci E Bakan S Gokturk S Cimilli T Utility diffusionweighted imaging evaluation liver fibrosis Eur Radiol 201222682687 30 Bonekamp S Torbenson MS Kamel IR Diffusionweighted magnetic resonance imaging staging liver fibrosis J Clin Gastroenterol 201145885892 9 Ichikawa T Haradome H Hachiya J et al Diffusionweighted MR 31 Woodhams Ramadan S Stanwell P et al Diffusionweighted Annals Gastroenterology 28 Diffusionweighted MRI liver fibrosis 123 Imaging breast Principles clinical applications Ragiographics 20113110591084 32 Boulanger Y Amara M Lepanto L et al Diffusion weighted MR imaging liver hepatitis C patients NMR Biomed 200316132136 33 Yamada I Aung W Himeno Y et al Diffusion coefficients abdominal organs hepatic lesions evaluation intravoxel incoherent motion imaging Radiology echoplanar MR 1999210617623 34 Ozkurt H Keskiner F Karatag O Alkim C Erturk SM Basak M Diffusion weighted MRI hepatic fibrosis impact bvalue Iran J Radiol 201411e3555 35 Girometti R Furlan A Esposito G et al Relevance bvalues evaluating liver fibrosis study healthy cirrhotic subjects singleshot spinecho echoplanar diffusionweighted sequences J Magn Reson Imaging 200828411419 36 Wang QB Zhu H Liu HL et al Performance magnetic resonance elastography diffusionweighted imaging staging hepatic fibrosis A metaanalysis Hepatology 20125623947 37 Papalavrentios L Sinakos E Chourmouzi D et al 3 Tesla diffusion weighted MRI assessing liver fibrosis nonalcoholic fatty liver disease Hepatology 201358449450 Annals Gastroenterology 28